News & Events

EP Vantage Releases its Annual Analysis of Pharma & Biotech and Medtech Sector Performance: 2015 in Review Reports

EP Vantage Releases its Annual Analysis of Pharma & Biotech and Medtech Sector Performance: 2015 in Review Reports

Future innovation at risk as venture capital dries up for early-stage companies

LONDON, BOSTON, SAN FRANCISCO, TOKYO (March 16, 2016) – Funding for early stage biopharma and medtech research dwindled in 2015, as investors shifted their support to more mature companies. These findings and more were released today as part of the Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd.

This venture investment trend, which began five years ago, could constrain future pharmaceutical and medtech innovation, as promising new scientific discoveries fail to progress due to lack of funding.

“Early stage investment is the lifeblood of the industry,” said Lisa Urquhart, Editor of EP Vantage.  “Our 2015 reports show it’s being given to an increasingly small pool of companies, which could cause some very serious problems in the future. Both medtech and pharma need a large cohort of startup companies to hedge against failure and foster innovation. Depriving them of funding now could eventually choke the industry.”

Other key findings include:

  • Drug pricing and sustainability issues took the air out of the biotech bubble, leading to the early 2016 market collapse, which negated almost all gains since mid-2014.
  • A shift toward mega investment rounds became evident in the pharma & biotech world. Top-10, triple-digit venture capital raises consumed nearly one quarter of all available funds for development-stage biotechs.
  • Pharma & Biotech FDA approvals jumped from an unprecedented 50 in 2014, to 57 in 2015
  • The total value of mergers and acquisitions in the medtech sector in 2015 reached an unprecedented high; a figure that held true even if the record-breaking acquisition of Covidien by Medtronic was excluded.
  • Questions remain about how the medtech sector can stimulate investing and deals for emerging to mid-size companies, to support sector innovation and growth.
  • A total of 51 novel medical devices were approved by the FDA in 2015, the most in a decade

The two reports published today offer analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2015. The reports are based on EvaluatePharma® and EvaluateMedTech® data.

To download the complimentary Pharma & Biotech 2015 in Review report, please visit
For the Medtech 2015 in Review report, please visit

About Evaluate Ltd
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our subscription services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Evaluate Custom Services provides project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit

On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, @epvantage.

Issued for and on behalf of Evaluate by Instinctif Partners.
For more information please contact:

back to news